Fig. 1 | Scientific Reports

Fig. 1

From: Analysis of nationwide adverse event reports on Isoniazid and Rifampin in tuberculosis prevention and treatment in South Korea

Fig. 1

Flowchart illustrating the selection process of adverse event (AE) reports from the Korea Adverse Event Reporting System (KAERS). AE reports extracted from the KAERS system, spanning between 2017 and 2021. Only the first or most recent completed reports were included and reports that were incomplete or canceled reports were excluded. Finally, suspected causative drugs associated with AEs were paired together. Suspected drugs were categorized into rifampin, isoniazid, or others drugs group.

Back to article page